Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Restorbio Inc (TORC) USD0.0001

Sell:$1.46 Buy:$1.47 Change: $0.04 (2.67%)
Market closed |  Prices as at close on 17 January 2020 | Switch to live prices |
Change: $0.04 (2.67%)
Market closed |  Prices as at close on 17 January 2020 | Switch to live prices |
Change: $0.04 (2.67%)
Market closed |  Prices as at close on 17 January 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

resTORbio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. It focuses on the mechanistic target of rapamycin (mTOR) pathway that regulates aging, and specifically on selective inhibition of the target of rapamycin complex 1 (TORC1). Its initial focus is on the development of RTB101, an orally administered, small molecule, potent TORC1 inhibitor, alone and in combination with other mTOR inhibitors, such as everolimus. Its product pipeline includes the TORC1 program that includes the development of RTB101 for various indications. The indications include respiratory tract infections, heart failure with preserved ejection fraction, autophagy related neurodegenerative diseases and other indications. The Company is developing RTB101 in a Phase II b clinical trial.

Contact details

500 Boylston St Fl 12
United States
+1 (617) 4822333

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$55.39 million
Shares in issue:
36.44 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Chen Schor
    President, Chief Executive Officer, Director
  • John McCabe
    Vice President - Finance
  • Erkan Baloglu
    Vice President - Drug Discovery and Medicinal Chemistry
  • Lloyd Klickstein
    Chief Scientific Officer
  • Joan Mannick
    Chief Medical Officer
  • Meredith Manning
    Chief Commercial Officer
  • Susan Stewart
    Head of Regulatory Affairs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.